Back to search page

RDGR20180503001

EuroNanoMed 3/2018-phase II (full proposal) – biotech SMEs from Spain, Latvia or Lithuania sought to develop new nano-immunomedicines for Alzheimer’s disease.

RESEARCH PROFILE   REQUEST   ADD TO FAVOURITES
PRINT

 

ABSTRACT

A consortium of 5 partners from Greece, France, Italy and Turkey coming from academia & the public health sector are preparing a full proposal on "Development of new nano-immunomedicines for Alzheimer’s disease" for the EuroNanoMed 3/2018 call. They are urgently looking for a biotech SME from Spain, Latvia or Lithuania with expertise in the large-scale production of monoclonal antibodies or specialized in the production of polymeric nanoparticles or liposomes.


FULL DESCRIPTION

A consortium consisting of 5 partners from 4 countries (Greece, France, Italy and Turkey) involving research groups from both academia and the clinical/public health research sector has recently submitted a pre-proposal for the category “Innovation applied research projects”, which passed the first evaluation step successfully and is now being submitted at the full proposal submission stage for the EuroNanoMed 3/2018 call.

The proposal aims to advance the development of effective immunotherapy for Alzheimer’s disease (AD) based on the use of nanoparticles. The current consortium members have significant expertise in nanotechnology, molecular biology, immunology and neurobiology, which is necessary for the proposal’s implementation.

They seek one additional partner, an SME, specifically from either Spain, Latvia or Lithuania.

They are urgently looking for:
1. A biotechnology SME capable of designing and implementing the large-scale production of monoclonal antibodies under GMP (Good Manufacturing Practice) conditions
or
2] a pharmaceutical or biotechnology SME specialized in the production of polymeric nanoparticles or liposomes

More information about the research proposal will be provided upon selection.

Call deadline: 30/05/2018
Deadline for Expressions of interest: 14/05/2018


Partner expertise sought:

- Specific area of activity of the partner: The consortium is urgently looking for:

1. A biotechnology SME to undertake the large-scale production - under GMP conditions - of the developed monoclonal antibodies against the two main target neuroantigens

Or

2. A pharmaceutical or biotechnology SME which will design and implement a larger (than lab) scale manufacturing process for the nanocarriers (polymeric nanoparticles or liposomes).

The selected SME will enter the consortium that will submit a joint full proposal for the EuroNanoMed 3/2018 call with deadline 30/05/18.


Development Stage:

Proposal under development

Programme - Call:

Evaluation scheme: Innovation applied research projects

Website: http://www.euronanomed.net/joint-calls/9th-joint-call-2018/

Deadline: 30/05/2018

Coordinator required: No

Sign-in or create an account

To express an interest in this profile, you must first sign in or create a new account.

If you already have an account, sign in here

Not got an account yet, sign up here

KEY INFORMATION

Country of origin
GREECE
Profile date
16/05/2018
Deadline
21/05/2018

PARTNERSHIP(S) SOUGHT

Research cooperation agreement

CLASSIFICATIONS

INDUSTRY SECTORS
Nanotechnology & Nanoscience \ Life Sciences \ Biosciences and Health \ Environment & Protecting Man \ Drug Discovery and Drug Development \ Medical Devices
TECHNOLOGY KEYWORDS
BIOLOGICAL SCIENCES / Medicine, Human Health / Medical Research / BIOLOGICAL SCIENCES / Medicine, Human Health / Pharmaceutical Products / Drugs / BIOLOGICAL SCIENCES / Micro- and Nanotechnology related to Biological sciences
COMMERCIAL KEYWORDS
none...
MARKET KEYWORDS
GENETIC ENGINEERING/MOLECULAR BIOLOGY / Micro- and Nanotechnology related to Biological sciences / MEDICAL/HEALTH RELATED / Anatomy, Pathology, Immunology, Physiology / MEDICAL/HEALTH RELATED / Other Medical/Health Related / Pharmaceuticals/fine chemicals

FIND OUT MORE

Contact Enterprise Europe Network Scotland by email at info@enterprise-europe-scotland.com, quoting reference number RDGR20180503001